Role of Serum Eosinophil Cationic Protein in the Monitoring of Children with Bronchial Asthma and Rhinitis

1998 ◽  
Vol 12 (2) ◽  
pp. 129-138 ◽  
Author(s):  
WEN-YI LEE ◽  
MEI-HUI YANG ◽  
LI-CHEN CHEN ◽  
SYH-JAE LIN ◽  
JING-LONG HUANG
Keyword(s):  
Bronchial Asthma ◽  
Eosinophil Cationic Protein ◽  
Cationic Protein

Serum eosinophil cationic protein in relation to bronchial asthma in a young Swedish population

Allergy ◽  
1994 ◽  
Vol 49 (9) ◽  
pp. 730-736 ◽  
Author(s):  
E. Björnsson ◽  
C. Janson ◽  
L. Håkansson ◽  
I. Enander ◽  
P. Venge ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Eosinophil Cationic Protein ◽  
Cationic Protein ◽  
Swedish Population

scholarly journals Eosinophil cationic protein (ECP) in saliva: a new marker of disease activity in bronchial asthma

2001 ◽  
Vol 95 (8) ◽  
pp. 670-675 ◽  
Author(s):  
B. SCHMEKEL ◽  
J. AHLNER ◽  
M. MALMSTRÖM ◽  
P. VENGE
Keyword(s):  
Disease Activity ◽  
Bronchial Asthma ◽  
Eosinophil Cationic Protein ◽  
Cationic Protein

Effects of Pranlukast Hydrate on Serum Eosinophil Cationic Protein Levels in Patients with Adult Bronchial Asthma

2011 ◽  
Vol 49 (01) ◽  
pp. 35-37
Author(s):  
Takahiko Horiguchi ◽  
Soichi Tachikawa ◽  
Junichi Kasahara ◽  
Masashi Doi ◽  
Mamoru Shiga
Keyword(s):  
Bronchial Asthma ◽  
Eosinophil Cationic Protein ◽  
Cationic Protein ◽  
Protein Levels

scholarly journals The serum eosinophil cationic protein concentration in patients with bronchial asthma and its correlation with severity and exacerbation of the disease

2003 ◽  
Vol 22 (3) ◽  
pp. 249-253
Author(s):  
Snezana Kovacevic ◽  
Mirjana Bogic ◽  
Aleksandra Peric-Popadic ◽  
Sanvila Raskovic ◽  
Zikica Jovicic ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Clinical Picture ◽  
Healthy Subjects ◽  
Protein Concentration ◽  
Geometric Mean ◽  
Eosinophil Cationic Protein ◽  
Cationic Protein ◽  
Asthmatic Patients ◽  
Severity Of Disease ◽  
Severity Of The Disease

Activated eosinophilic leukocyte in asthma secretes numerous mediators, among which is ECP as well. The object of our study was to measure the serum ECP concentrations in 46 asthmatic patients with exacerabating and stable asthma, and to correlate the serum ECP concentrations with severity and exacerbation of the disease. Geometric mean of ECP in serum (Gecp) in our group of patients was 7.5 mcg/l, while it was 3.05 mcg/l in the 15 healthy subjects (controls). Highly significant correlation of serum ECP concentrations with the activity of the disease (R=0.897) and the severity of clinical picture (R=0.79) was found. The patients with stable asthma had significant correlation of ECP and the severity of disease (R=0.6). The patients with exacerbating asthma have significantly higher serum ECP concentrations than the patients with stable asthma. Serum ECP concentrations in patients with exacerbating asthma correlate with the severity of the disease.

Usefulness of Sparfloxacin against Chlamydia pneumoniae Infection in Patients with Bronchial Asthma

2005 ◽  
Vol 33 (6) ◽  
pp. 668-676
Author(s):  
T Horiguchi ◽  
J Miyazaki ◽  
D Ohira ◽  
Y Watanabe ◽  
N Hayashi ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Chlamydia Pneumoniae ◽  
Eosinophil Cationic Protein ◽  
Treated Group ◽  
Control Treatment ◽  
Cationic Protein ◽  
Stimulant Use ◽  
Protein Levels ◽  
Reactive Protein ◽  
Reduced Frequency

The efficacy of Sparfloxacin (SPFX) for the control of bronchial asthma was evaluated in 26 patients with suspected Chlamydia pneumoniae infection. Patients were randomly allocated to receive SPFX 200 mg/day (n = 14) or control treatment (n = 12) for 21 days. Significant improvements in serum C-reactive protein levels, and significant decreases in peripheral eosinophil counts, serum eosinophil cationic protein (ECP) and sputum ECP were observed in the SPFX-treated group at day 21. SPFX-treated patients also had a significantly reduced frequency of asthma symptoms, reduced inhalant β2-stimulant use, and significant increases in morning peak expiratory flow. At the end of the study, C. pneumoniae was undetectable in two SPFX-treated patients who underwent polymerase chain reaction testing, but one control patient who was tested still had detectable levels of C. pneumoniae. These results suggest that SPFX could be used to control bronchial asthma in patients with suspected persistent C. pneumoniae infection.

The role of eosinophils and eosinophil cationic protein in oral cancer: A review

2011 ◽  
Vol 56 (4) ◽  
pp. 353-358 ◽  
Author(s):  
Michele Conceição Pereira ◽  
Denise Tostes Oliveira ◽  
Luiz Paulo Kowalski
Keyword(s):  
Oral Cancer ◽  
Eosinophil Cationic Protein ◽  
Cationic Protein
Sign in / Sign up

Export Citation Format

Share Document